Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2022; 28(33): 4773-4786
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4773
Albumin administration in patients with cirrhosis: Current role and novel perspectives
Ângelo Zambam de Mattos, Douglas Alano Simonetto, Carlos Terra, Alberto Queiroz Farias, Paulo Lisboa Bittencourt, Tales Henrique Soares Pase, Marlon Rubini Toazza, Angelo Alves de Mattos, Alliance of Brazilian Centers for Cirrhosis Care – the ABC Group
Ângelo Zambam de Mattos, Angelo Alves de Mattos, Graduate Program in Medicine: Hepatology, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, Brazil
Douglas Alano Simonetto, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55902, United States
Carlos Terra, Department of Gastroenterology, State University of Rio de Janeiro, Rio de Janeiro 20550-170, Brazil
Alberto Queiroz Farias, Department of Gastroenterology, University of São Paulo, São Paulo 01246-903, Brazil
Paulo Lisboa Bittencourt, Gastroenterology and Hepatology Unit, Hospital Português, Salvador 40130-030, Brazil
Tales Henrique Soares Pase, Internal Medicine Unit, Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre 90020-090, Brazil
Marlon Rubini Toazza, Gastroenterology and Hepatology Unit, Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre 90020-090, Brazil
Author contributions: All authors contributed to this paper with conception of the manuscript, literature review and analysis, drafting and critical revision of the manuscript, and approval of the final version of the paper.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ângelo Zambam de Mattos, MD, MSc, PhD, Professor, Graduate Program in Medicine: Hepatology, Federal University of Health Sciences of Porto Alegre, 245, Sarmento Leite Street, Porto Alegre 90050-170, Brazil. angmattos@hotmail.com
Received: March 27, 2022
Peer-review started: March 27, 2022
First decision: May 9, 2022
Revised: June 5, 2022
Accepted: July 5, 2022
Article in press: July 5, 2022
Published online: September 7, 2022
Core Tip

Core tip: Mortality in cirrhosis is mostly associated with clinical decompensation. Albumin has oncotic and nononcotic properties, which may contribute to the prevention and management of such complications. This review discusses the current recommendations and the novel perspectives regarding the use of albumin in cirrhosis.